Who
William K. Heiden
Director
Company insider
Files Form 4 as: Director, Atara Biotherapeutics; Director, MacroGenics; President & CEO, Amag Pharmaceuticals; Chairman, President and CEO, Gtc Biotherapeutics.
In numbers
- Trades disclosed
- 108
- Buys
- 6
- Sells
- 8
- Bought
- $283K
- Sold
- $7.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Oct 2009
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 20 Aug 2025filed 21 Aug 2025 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Bought | $74K49,500 at $1.49 | filing |
| 19 Aug 2025filed 21 Aug 2025 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Bought | $77K50,500 at $1.52 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,828 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,500 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —6,500 | filing |
| 21 May 2024filed 23 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,500 at $0.00 | filing |
News
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNMGNX · manilatimes.net · 23 Oct 2026MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name William K. Heiden; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.